Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology

NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million

Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex

Philogen updates on Fibromun clinical study developments

FIBROSARC did not meet its primary PFS endpoint in the final analysi

Lupin receives EIR from FDA for its Aurangabad facility

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg